351 related articles for article (PubMed ID: 26522271)
1. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
[TBL] [Abstract][Full Text] [Related]
3. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Naagaard MD; Chang R; Någård M; Tang W; Boulton DW
Br J Clin Pharmacol; 2022 Feb; 88(4):1942-1946. PubMed ID: 34687551
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
5. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
Chang YK; Choi H; Jeong JY; Na KR; Lee KW; Lim BJ; Choi DE
PLoS One; 2016; 11(7):e0158810. PubMed ID: 27391020
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
[TBL] [Abstract][Full Text] [Related]
9. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Calado J
IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
14. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
[TBL] [Abstract][Full Text] [Related]
15. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
[TBL] [Abstract][Full Text] [Related]
16. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Chao EC
Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
[TBL] [Abstract][Full Text] [Related]
19. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]